FEB 24, 2018 12:50 PM PST

Tumors Eradicated by Immune-stimulating Agents

WRITTEN BY: Carmen Leitch

With mice as a model, researchers at Stanford discovered that by injecting two molecules that stimulate the immune system, solid tumors and any trace of cancer could be eliminated. This T cell activating therapy could work for many types of cancer. Because only small amounts are needed in a targeted approach, the researchers believe this could be an affordable treatment that doesn’t cause as many side effects as other therapeutics.

A scanning electron micrograph of a healthy human T cell. / Credit: NIH

“When we use these two agents together, we see the elimination of tumors all over the body,” noted Ronald Levy, MD, professor of oncology. He was senior author of a report in Science Translational Medicine summarizing the findings. “This approach bypasses the need to identify tumor-specific immune targets and doesn’t require wholesale activation of the immune system or customization of a patient’s immune cells.”

One drug is already approved for human use, and the other has undergone testing for human patients in a few unrelated clinical trials. This January, a new clinical trial was launched to assess this treatment in lymphoma patients.

There has been considerable interest in developing drugs that use the immune system to fight cancer. Some approaches rely on bodywide stimulation; others remove a patient’s immune cells and genetically alter them to combat cancer before reinjecting them. While there have been other attempts as well, none have been entirely successful. Some are very expensive or laborious; others cause serious side effects. 

“All of these immunotherapy advances are changing medical practice,” Levy said. “Our approach uses a one-time application of very small amounts of two agents to stimulate the immune cells only within the tumor itself. In the mice, we saw amazing, bodywide effects, including the elimination of tumors all over the animal.”

Typically, cells of the immune system that should recognize foreign invaders, T cells, will attack cancer cells at first, but as cancerous tumors grow, they are often able to suppress T cell activity.

Levy’s team aimed to stimulate T cells that target cancer by exposing them to minuscule amounts of two agents at the site of tumors. One is a short snippet of DNA called an oligonucleotide; it boosts the expression of a T cell receptor. The other molecule is an antibody that binds to that receptor. Together, the antibody and receptor team up to activate the T cells. Only T cells that have gotten into the tumor are activated since the agents are applied to the tumor directly. Those T cells can recognize a specific cancer, and some leave the site of the tumor. They then migrate throughout the body and destroy other, similar tumors.

This was a remarkably effective approach that worked in transplanted lymphoma tumors, with both the original injected tumor getting destroyed as well as a second, uninjected tumor. The therapy also worked on genetically engineered mice that develop breast cancer. In the cases of cancers that grew back after the first treatment, a second treatment removed it again.

After testing mice that had been transplanted to receive lymphoma tumors and colon cancer, the treatment eliminated the lymphoma tumors, but not the colon cancer.

“This is a very targeted approach,” Levy explained. “Only the tumor that shares the protein targets displayed by the treated site is affected. We’re attacking specific targets without having to identify exactly what proteins the T cells are recognizing.”

If the current trial, which will have around fifteen lymphoma patients, is successful, the researchers want to find out if it works with other kinds of cancer.

“I don’t think there’s a limit to the type of tumor we could potentially treat, as long as it has been infiltrated by the immune system,” Levy said.


Sources: Stanford University, Science Translational Medicine

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUL 14, 2020
Coronavirus
What Makes A Strong Antibody Response to Coronavirus
JUL 14, 2020
What Makes A Strong Antibody Response to Coronavirus
Scientists all over the world are racing to develop a vaccine that effectively and safely prompts protective immunity to ...
JUL 26, 2020
Neuroscience
How COVID-19 Causes Loss of Smell
JUL 26, 2020
How COVID-19 Causes Loss of Smell
Temporary loss of smell, known as anosmia, is one of the most common early indicators of COVID-19. Although some say it ...
AUG 19, 2020
Immunology
Cancer Mutation Improves Chemo Drug Performance
AUG 19, 2020
Cancer Mutation Improves Chemo Drug Performance
When it comes to cancer biomarkers, it’s often the genetic signatures that are associated with poor patient outcom ...
AUG 23, 2020
Cell & Molecular Biology
A Potential Breakthrough in Type 1 Diabetes Treatment
AUG 23, 2020
A Potential Breakthrough in Type 1 Diabetes Treatment
Salk Institute researchers created 3D cell clusters that can produce insulin, which is shown in green in their image.
SEP 06, 2020
Cell & Molecular Biology
The Beginnings of a Protein Are Captured in 3D
SEP 06, 2020
The Beginnings of a Protein Are Captured in 3D
There are many genes in the DNA that gives rise to an organism, and genes that code for protein are a critical part of t ...
SEP 11, 2020
Genetics & Genomics
A Better Understanding of Telomere Length Throughout the Body
SEP 11, 2020
A Better Understanding of Telomere Length Throughout the Body
Telomeres cap the ends of chromosomes. They work to protect the chromosomes from degradation, and are known to get short ...
Loading Comments...